Search

358 Result(s)
Sort by

Our partners Bioveta

Our partners Bioveta

Our partner Bioveta shares insights about the longstanding collaboration with Boehringer Ingelheim and the evolution of the partnership
biologicals-development-center

biologicals-development-center

Europe’s largest biotechnology center in Biberach, Germany is the home to three development units.
China pioneers biosecurity report against ASF

China pioneers biosecurity report against ASF

Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Cancer's Big 4

Cancer's Big 4

We have a robust pipeline of clinical assets including cancer cell-directed therapies, for which we are investigating the key drivers of cancer such as P53 and KRAS.
Combination Therapy

Combination Therapy

It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Biostatistics & Data Science

Biostatistics & Data Science

Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
sustainably fighting rabies info hub

sustainably fighting rabies info hub

Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Our Partners Bioharmony

Our Partners Bioharmony

Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
The big, the bold, and the few

The big, the bold, and the few

In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?